Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib in plasma ctDNA EGFR mutation-positive lung cancer
NCT03346811Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Primary endpoint: Objective Response Rate at 12 weeks. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03346811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346811.